Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab vs Chemotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma
NCT04342936Phase 3Unknown
- Sponsor
- Hengrui
- Start
- Jul 2020
- Primary completion
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab in classical Hodgkin lymphoma (cHL), sponsored by Hengrui. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT04342936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04342936.